Abstract:Advanced non-small cell lung cancer (NSCLC) leads to a high death rate in patients and is a major threat to human health. NSCLC induces an immune suppressive microenvironment and escapes from immune surveillance in vivo. At present, the molecular mechanisms of NSCLC immunopathogenesis and the immune suppressive microenvironment induced by NSCLC have not been fully elucidated. Here, we focus on the effect of NSCLC cells on the development and differentiation of human CD1c+ conventional dendritic cell (DC) subsets mediated by CD205 and CD103. The peripheral blood mononuclear cells (PBMCs) were isolated from NSCLC patients and healthy donors. DCs were induced and cocultured with primary NSCLC cells or tumor cell line H1299. DCs without incubation with tumor cells are control. The protein expression of costimulatory molecules such as CD80 and CD86, HLA-DR, pro-/anti-inflammatory cytokines such as IL-10 and IL-12, and CD205 and CD103 on CD1c+ DCs was detected by flow cytometry. Our data revealed two new subpopulations of human CD1c+ DCs (CD1c+CD205+CD103+ and CD1c+CD205+CD103- DC) in healthy donors and NSCLC patients. NSCLC cells modulate the development of the CD1c+CD205+CD103+ DC and CD1c+CD205+CD103- DC subpopulations in vitro and ex vivo. NSCLC cells also suppress the expression of signal molecules such as CD40, CD80, CD86, and HLA-DR on CD1c+ DCs. In addition, the production of pro-inflammatory cytokines, including IL-12 and IL-23, is downregulated by NSCLC cells; however, the secretion of anti-inflammatory cytokines, such as IL-10 and IL-27, by CD1c+ DCs is upregulated by NSCLC cells. Our results suggest that NSCLC cells may induce immune tolerogenic DCs, which block DC-mediated anti-tumor immunity in NSCLC patients. Our data may be helpful in revealing new cellular mechanisms related to the induction of tolerogenic CD1c+ DCs by NSCLCs and the development of an immune suppressive microenvironment that causes tumor cells to escape immune surveillance. Our results indicate a potential role for CD1c+ DC subsets mediated by CD205 and CD103 in DC-mediated immunotherapy to target NSCLC in the future.

Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC

Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c+ Conventional Dendritic Cell Subsets Mediated by CD103 and CD205

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Cd1d Highly Expressing On Dcs Reduces Lung Tumor Burden By Enhancing Anti-Tumor Immunity

CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer

The differentiation of new human CD303+ Plasmacytoid dendritic cell subpopulations expressing CD205 and/or CD103 regulated by Non-Small-Cell lung cancer cells

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation

Critical Role of Dendritic Cell-Derived Il-27 in Antitumor Immunity Through Regulating the Recruitment and Activation of Nk and Nkt Cells

FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy

Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Mechanisms of CD40-dependent cDC1 licensing beyond costimulation

Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer

Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review

Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy

BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance